La Jolla Pharmaceutical Company (LJPC) stock price, revenue, and financials

La Jolla Pharmaceutical Company market cap is $118.7 m, and annual revenue was $23.05 m in FY 2019

$118.7 M

LJPC Mkt cap, 27-Mar-2020

$23.1 M

La Jolla Pharmaceutical Company Revenue FY, 2019
La Jolla Pharmaceutical Company Gross profit (FY, 2019)20.7 M
La Jolla Pharmaceutical Company Gross profit margin (FY, 2019), %89.6%
La Jolla Pharmaceutical Company Net income (FY, 2019)-116.5 M
La Jolla Pharmaceutical Company EBIT (FY, 2019)-109.8 M
La Jolla Pharmaceutical Company Cash, 31-Dec-201987.8 M
La Jolla Pharmaceutical Company EV57.3 M

La Jolla Pharmaceutical Company Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.1m616.0k10.1m23.1m

Cost of goods sold

1.6m2.4m

Gross profit

8.4m20.7m

Gross profit Margin, %

84%90%

R&D expense

177.0k1.4m4.4m9.9m29.1m62.3m84.6m117.3m85.3m

General and administrative expense

2.1m9.4m13.6m11.4m13.9m16.7m30.9m85.2m45.1m

Operating expense total

2.3m10.7m17.9m21.3m43.0m79.0m115.4m202.5m130.5m

EBIT

(2.3m)(10.7m)(17.9m)(21.3m)(42.0m)(78.4m)(115.4m)(194.1m)(109.8m)

EBIT margin, %

(3971%)(12723%)(1930%)(476%)

Interest expense

6.7m

Interest income

1.9m2.1m

Income tax expense

Net Income

(11.5m)(7.7m)(17.9m)(21.3m)(41.9m)(78.2m)(114.8m)(199.5m)(116.5m)

La Jolla Pharmaceutical Company Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

5.8m5.5m4.4m3.8m3.4m2.7m1.8m10.7m5.9m3.9m54.1m42.7m36.0m135.1m113.1m100.6m85.0m162.4m141.3m120.8m154.4m241.4m204.3m140.0m123.4m104.8m

Accounts Receivable

372.0k1.5m2.0m1.9m1.4m

Prepaid Expenses

19.0k9.0k50.0k97.0k40.0k76.0k67.0k47.0k156.0k148.0k153.0k622.0k622.0k484.0k1.4m1.4m1.4m1.7m1.8m1.8m6.3m5.3m5.8m5.1m5.1m4.8m

Inventories

820.0k2.0m2.0m1.9m

Current Assets

5.8m5.5m4.4m3.9m3.4m2.8m1.9m10.8m6.1m4.1m54.3m44.8m37.2m136.1m114.7m102.3m86.7m164.4m144.0m123.5m161.6m248.0m212.8m149.1m132.4m112.9m

PP&E

37.0k37.0k51.0k89.0k114.0k659.0k1.5m1.8m2.0m2.3m2.6m3.6m4.6m6.5m24.4m24.2m23.3m21.3m20.4m19.5m

Total Assets

5.8m5.5m4.4m3.9m3.4m2.8m2.0m10.8m6.1m4.2m54.4m45.5m38.7m137.9m117.0m104.8m89.5m168.0m148.6m130.1m186.9m273.1m237.1m187.8m169.9m149.1m

Accounts Payable

26.0k23.0k36.0k129.0k68.0k69.0k176.0k473.0k562.0k917.0k683.0k2.5m1.8m2.6m2.4m2.3m2.0m4.2m5.9m6.2m7.3m6.1m6.6m3.0m4.9m5.3m

Short-term debt

Current Liabilities

6.9m2.6m9.7m14.0m12.9m271.0k308.0k577.0k906.0k1.1m1.6m2.6m2.5m4.3m5.2m5.2m7.2m5.7m8.3m10.3m16.0m19.0m23.9m17.2m22.0m22.5m

Long-term debt

28.6m27.9m27.2m

Total Debt

28.6m27.9m27.2m

Total Liabilities

29.5m157.5m162.1m176.5m182.5m184.3m

Common Stock

3.0k6.0k4.0k5.0k5.0k2.0k3.0k21.0k4.0k4.0k4.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k3.0k3.0k3.0k3.0k3.0k3.0k

Preferred Stock

3.6m3.6m3.6m

Additional Paid-in Capital

423.5m424.0m420.2m422.7m425.3m443.2m445.1m458.8m467.2m471.1m525.9m531.9m535.8m643.7m650.2m653.5m657.5m785.6m790.4m796.1m922.8m933.8m943.9m959.9m966.4m973.0m

Retained Earnings

(429.9m)(426.3m)(434.3m)(442.0m)(444.3m)(451.6m)(454.7m)(458.9m)(470.4m)(474.7m)(479.8m)(495.6m)(506.2m)(516.7m)(545.0m)(560.6m)(581.8m)(630.0m)(656.7m)(683.0m)(772.0m)(824.8m)(875.6m)(952.5m)(982.9m)(1.0b)

Total Equity

(6.4m)(2.3m)(10.6m)(15.7m)(15.3m)2.5m1.7m10.2m5.2m3.1m52.8m43.0m36.2m133.6m111.8m99.6m82.3m162.3m140.3m119.8m157.4m115.7m75.0m11.3m(12.6m)(35.2m)

Financial Leverage

-0.9 x-2.4 x-0.4 x-0.2 x-0.2 x1.1 x1.2 x1.1 x1.2 x1.3 x1 x1.1 x1.1 x1 x1 x1.1 x1.1 x1 x1.1 x1.1 x1.2 x2.4 x3.2 x16.6 x-13.5 x-4.2 x

La Jolla Pharmaceutical Company Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(11.5m)(7.7m)(17.9m)(21.3m)(41.9m)(78.2m)(114.8m)(199.5m)(116.5m)

Depreciation and Amortization

5.0k17.0k347.0k730.0k1.3m4.4m4.6m

Accounts Receivable

(1.4m)(1.6m)

Inventories

(2.0m)(191.0k)

Accounts Payable

31.0k(49.0k)822.0k(104.0k)1.8m3.6m4.8m(2.9m)(4.4m)

Cash From Operating Activities

(1.8m)(2.1m)(4.7m)(12.9m)(25.2m)(58.7m)(84.9m)(152.4m)(84.9m)

Purchases of PP&E

(43.0k)(258.0k)(1.8m)(2.2m)(9.2m)(2.3m)(698.0k)

Cash From Investing Activities

(43.0k)(258.0k)(1.8m)(2.2m)(9.2m)(2.3m)(698.0k)

Cash From Financing Activities

500.0k10.0m53.1m104.9m149.0k119.3m236.4m864.0k

Net Change in Cash

(1.8m)(1.6m)5.2m39.9m77.9m(60.7m)25.2m81.7m(84.8m)

Interest Paid

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(1.8m)1.8m5.3m(2.4m)(4.6m)(4.2m)(7.4m)(11.5m)(5.1m)(9.4m)(14.5m)(9.0m)(19.6m)(30.1m)(16.5m)(32.0m)(53.3m)(23.2m)(50.0m)(76.3m)(50.5m)(103.3m)(154.1m)(31.7m)(62.1m)(91.3m)

Depreciation and Amortization

1.0k3.0k2.0k5.0k10.0k11.0k95.0k209.0k142.0k310.0k510.0k281.0k581.0k899.0k992.0k2.1m3.2m1.1m2.3m3.4m

Accounts Receivable

(372.0k)(1.5m)(618.0k)(512.0k)(36.0k)

Inventories

43.0k52.0k110.0k

Accounts Payable

(92.0k)(43.0k)28.0k121.0k60.0k46.0k68.0k322.0k(197.0k)(46.0k)562.0k1.7m1.1m1.8m(98.0k)(250.0k)(508.0k)(2.5m)(732.0k)(413.0k)(4.2m)(5.4m)(4.9m)(5.5m)(3.7m)(3.2m)

Cash From Operating Activities

(1.1m)(1.4m)(659.0k)(1.2m)(1.7m)(705.0k)(1.5m)(2.6m)(2.7m)(4.7m)(7.5m)(5.5m)(11.2m)(16.7m)(13.0m)(25.1m)(40.1m)(22.1m)(41.9m)(60.4m)(45.8m)(83.4m)(120.3m)(32.7m)(49.2m)(67.8m)

Purchases of PP&E

(38.0k)(40.0k)(15.0k)(56.0k)(86.0k)(391.0k)(1.3m)(1.7m)(478.0k)(910.0k)(1.4m)(750.0k)(2.0m)(4.3m)(994.0k)(1.9m)(2.3m)(184.0k)(441.0k)(679.0k)

Cash From Investing Activities

(38.0k)(77.0k)(15.0k)(56.0k)(86.0k)(391.0k)(1.3m)(1.7m)(478.0k)(910.0k)(1.4m)(750.0k)(2.0m)(4.3m)(994.0k)(1.9m)(2.3m)(184.0k)(441.0k)(679.0k)

Dividends Paid

(374.0k)374.0k

Cash From Financing Activities

10.0m53.1m57.0k57.0k104.9m85.0k85.0k85.0k119.6m119.6m119.8m110.3m235.8m236.0m283.0k484.0k661.0k

Net Change in Cash

(1.1m)(1.4m)(659.0k)(1.2m)(1.7m)(705.0k)(1.6m)7.3m(2.7m)(4.7m)45.5m(5.8m)(12.5m)86.5m(13.4m)(25.9m)(41.4m)96.7m75.6m55.1m63.5m150.5m113.4m(32.6m)(49.2m)(67.8m)

La Jolla Pharmaceutical Company Ratios

USDY, 2019

EV/EBIT

-0.5 x

EV/CFO

-0.7 x

Revenue/Employee

136.4k

Financial Leverage

-2.4 x